The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gynecologic Cancers

No abstract is available for this paper.

• Publication year

  1999

• Venue

  The Annals of Pharmacotherapy

• Publication date

  1999-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1345/aph.18463PMID 10630832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

  2004cited by this paper
• The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

  2000cited by this paper
• Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women.

  1999cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Estrogen-progestin replacement therapy and endometrial cancer.

  1998cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group.

  1997cited by this paper
• Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.

  1997cited by this paper
• Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.

  1997cited by this paper
• The Role of Hormone Replacement Therapy in the Risk for Breast Cancer and Total Mortality in Women with a Family History of Breast Cancer

  1997cited by this paper
• Estrogen-Progestin Replacement Therapy and Endometrial Cancer

  1997cited by this paper
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  1997cited by this paper
• In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators.

  1997cited by this paper
• Effects on bone mass after eight years of hormonal replacement therapy

  1997cited by this paper
• Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.

  1997cited by this paper
• Hormonal therapy increases arterial compliance in postmenopausal women.

  1997cited by this paper
• Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

  1996cited by this paper
• Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy.

  1996cited by this paper
• The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.

  1996cited by this paper
• A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

  1996cited by this paper
• Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study.

  1996cited by this paper
• Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.

  1996cited by this paper
• The economic and human costs of osteoporotic fracture.

  1995cited by this paper
• The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

  1995cited by this paper
• Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.

  1995cited by this paper
• Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.

  1995cited by this paper
• Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women.

  1995cited by this paper
• Estrogen Replacement Therapy and Fractures in Older Women

  1995cited by this paper
• The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.

  1995cited by this paper
• Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

  1995cited by this paper
• Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.

  1995cited by this paper
• Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women.

  1995cited by this paper
• Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group.

  1995cited by this paper
• Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group.

  1994cited by this paper
• Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women

  1994cited by this paper
• Human vascular smooth muscle cells contain functional estrogen receptor.

  1994cited by this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cited by this paper
• Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations.

  1994cited by this paper
• Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women.

  1994cited by this paper
• Raloxifene preserves bone strength and bone mass in ovariectomized rats.

  1994cited by this paper
• Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis

  1993cited by this paper
• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.

  1993cited by this paper
• The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women.

  1993cited by this paper
• The effect of postmenopausal estrogen therapy on bone density in elderly women.

  1993cited by this paper
• Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen

  1992cited by this paper
• Diagnosis of Osteoporosis

  1992cited by this paper
• Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis

  1992cited by this paper
• Menopausal Estrogen Replacement Therapy and Breast Cancer

  1991cited by this paper
• A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

  1991cited by this paper
• Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.

  1991cited by this paper
• Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.

  1991cited by this paper
• Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women.

  1991cited by this paper
• A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

  1991cited by this paper
• Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆

  1991cited by this paper
• Mortality following hip fracture before and after implementation of the prospective payment system.

  1990cited by this paper
• Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women.

  1990cited by this paper
• The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen.

  1990cited by this paper
• A Prospective 1-Year Study of Estrogen and Progestin in Postmenopausal Women: Effects on the Endometrium

  1989cited by this paper
• Postmenopausal use of estrogen and occlusion of coronary arteries

  1988cited by this paper
• Postmenopausal estrogen use and coronary atherosclerosis.

  1988cited by this paper
• Postmenopausal use of estrogen and occlusion of coronary arteries.

  1988cited by this paper
• Evidence of estrogen receptors in normal human osteoblast-like cells.

  1988cited by this paper
• Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

  1987cited by this paper
• A prospective study of postmenopausal estrogen therapy and coronary heart disease.

  1985cited by this paper
• Amenorrhea and Endometrial Atrophy With Continuous Oral Estrogen and Progestogen Therapy in Postmenopausal Women

  1985cited by this paper
• Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.

  1984cited by this paper
• Clinical use of progestins in the menopausal patient: dosage and duration.

  1982cited by this paper

• Lipid Profile in Patients With Primary Ovarian Insufficiency: A Systematic Review and Meta-Analysis

  2022influential citation
• Combined Effects of Phytoestrogen Genistein and Silicon on Ovariectomy-Induced Bone Loss in Rat

  2017cites this paper
• Novel peptide-derived cathepsin K inhibitors from Streptomyces

  2010cites this paper
• Sex hormones and related compounds, including hormonal contraceptives

  2007cites this paper
• Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment

  2006cites this paper
• The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.

  2005cites this paper
• Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene

  2005cites this paper
• Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women

  2004cites this paper
• Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women

  2004cites this paper
• Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women

  2004cites this paper
• Efeitos do raloxifeno sobre a concentração plasmática de homocisteína e o lipidograma em mulheres na pós-menopausa

  2004cites this paper
• RBGO no 07-vol 26-2004.pmd

  2004cites this paper
• Hormone replacement therapy and breast carcinoma risk in Hispanic and non‐Hispanic women

  2002cites this paper
• Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment.

  2001cites this paper
• Economic Evaluation of Three Preventive Drug Therapies for Osteoporotic Fractures among Women at Different Risk levels

  2001cites this paper
• Identification of estrogen-responsive genes in chick liver

  2001cites this paper
• Oestrogen Agonisten und Antagonisten für mehrere Indikationen

  2000cites this paper
• Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy.

  2000cites this paper